Nizatidine for prevention of weight gain with olanzapine: A double-blind placebo-controlled trial

European Neuropsychopharmacology

Volumn 13, Issue 2, 2003, Pages 81-85

  Cavazzoni, Patrizia ^a   Tanaka, Yoko ^a   Roychowdhury, Suraja M ^a   Breier, Alan ^a   Allison, David B ^b  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

H 2 blockade; Nizatidine; Olanzapine; Weight gain

Indexed keywords

NIZATIDINE; OLANZAPINE;

ADULT; AGED; ANXIETY; ARTICLE; CLINICAL TRIAL; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG ELIMINATION; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; INCREASED APPETITE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NAUSEA; PRIORITY JOURNAL; SCHIZOPHRENIA; SCREENING; SIDE EFFECT; SOMNOLENCE; STATISTICAL SIGNIFICANCE; VERTIGO; WEIGHT GAIN; XEROSTOMIA;

EID: 0037338491     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(02)00127-X     Document Type: Article

References (27)

1. Allison D.B., Mentore J.L., Heo M., Chandler L.P., Cappelleri J.C., Infante M.C., Weiden P.J. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry. 156:(11):1999;1686-1696. Review.
2. Amdisen A. Drug-produced obesity: experiences with chlorpromazine, perphenazine and chlopenthixol. Dan. Med. Bull. 11:1964;182-189.
3. Andersen T., Hojby Rasmussen M. Cimetidine and obesity: conflicting evidence. Int. J. Obes. Relat. Metab. Disord. 23:(5):1999;550-551.
4. Birketvedt G.S., Thom E., Bernersen B., Florholmen J. Combination of diet, exercise and intermittent treatment of cimetidine on body weight and maintenance of weight loss. A 42 months follow-up study. Med. Sci. Monit. 6:(4):2000;699-703.
5. Borison R.L., Arvanitis L.A., Miller B.G. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. US SEROQUEL Study Group. J. Clin. Psychopharmacol. 16:(2):1996;158-169.
6. Breier A., Clark W.S., Tanaka Y., Roychowdhury S.M. Nizatidine for the prevention of olanzapine-associated weight gain in schizophrenia and related disorders: a randomized controlled double-blind study. Presented at the American Psychiatric Association, New Orleans. 2001.
7. Brunton L.L. Agents for the control of gastric acidity and treatment of peptic ulcers. 8th Edition Goodman and Gilman's The Pharmacological Basis of Therapeutics. 1990;897-913 McGraw Hill, New York.
8. Bymaster F.P., Calligaro D.O., Falcone J.F., Marsh R.D., Moore N.A., Tye N.C., Seeman P., Wong D.T. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 14:(2):1996;87-96.
9. COSTART: Coding Symbols for Thesaurus of Adverse Reaction Terms. 1995;US Department of Health and Human Services, Rockville, MD.
10. Fukagawa K., Sakata T., Shiraishi T., Yoshimatsu H., Fujimoto K., Ookuma K., Wada H. Neuronal histamine modulates feeding behavior through H1-receptor in rat hypothalamus. Am. J. Physiol. 256:(3 Pt. 2):1989;R605-611.
11. Gillings D., Koch G. The application of the principle of intent-to-treat to the analysis of clinical trials. Drug Info. J. 25:1991;411-425.
12. James W.P., Astrup A., Finer N., Hilsted J., Kopelman P., Rossner S., Saris W.H., Van Gaal L.F. Effect of sibutramine on weight maintenance after weight loss: a randomized trial. STORM Study Group. Lancet. 356:2000;2119-2125.
13. Kraly F.S., Katz J.B., Burchard A.E., Case C., Gabriel V.A., Lanz T.A., Mikkelsen M.E., Sokol M.B. H2 histaminergic control of inhibition of eating induced by intragastric NaCl in rats. Physiol. Behav. 65:(1):1998;105-113.
14. Lamberti J.S., Bellnier T., Schwarzkopf S.B. Weight gain among schizophrenic patients treated with clozapine. Am. J. Psychiatry. 149:(5):1992;689-690.
15. Lustig R.H. The neuroendocrinology of obesity. Endocrinol. Metab. Clin. North Am. 30:(3):2001;765-785.
16. Long-term pharmacotherapy in the management of obesity. J. Am. Med. Assoc. 276:(23):1996;1907-1915. Review.
17. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br. J. Psychiatry. 166:(6):1995;712-726. Discussion 727-733.
18. Sacchetti E., Guarneri L., Bravi D. H(2) antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients. Biol. Psychiatry. 48:(2):2000;167-168.
19. Sakata T., Yoshimatsu H., Kurokawa M. Hypothalamic neuronal histamine: implications of its homeostatic control of energy metabolism. Nutrition. 13:(5):1997;403-411. Review.
20. Schotte A., Janssen P.F., Gommeren W., Luyten W.H., Van Gompel P., Lesage A.S., De Loore K., Leysen J.E. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl.). 124:(1-2):1996;57-73.
21. Simpson G.M., Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. Suppl. 212:1970;11-19.
22. Stahl S.M. Neuropharmacology of obesity: my receptors made me eat it. J. Clin. Psychiatry. 59:(9):1998;447-448.
23. Stoa-Birketvedt G. Effect of cimetidine suspension on appetite and weight in overweight subjects. Br. Med. J. 30:(6885):1993;1091-1093.
24. Stoa-Birketvedt G., Lovhaug N., Vonen B., Florholmen J. H2-receptor antagonist reduces food intake and weight gain in rats by non-gastric acid secretory mechanisms. Acta Physiol. Scand. 161:(4):1997;489-494.
25. Stoa-Birketvedt G., Paus P.N., Ganss R., Ingebretsen O.C., Florholmen J. Cimetidine reduces weight and improves metabolic control in overweight patients with type 2 diabetes. Int. J. Obes. Relat. Metab. Disord. 22:(11):1998;1041-1045.
26. Stoa-Birketvedt G., Waldum H.L., Vonen B., Florholmen J. Effect of cimetidine on basal and postprandial plasma concentrations of cholecystokinin and gastrin in humans. Acta Physiol. Scand. 159:(4):1997;321-325.
27. Tollefson G.D., Beasley C.M. Jr., Tran P.V., Street J.S., Krueger J.A., Tamura R.N., Graffeo K.A., Thieme M.E. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am. J. Psychiatry. 154:(4):1997;457-465.